Abiomed Inc. (ABMD) CEO Michael R. Minogue Sells 5,034 Shares
Abiomed Inc. (NASDAQ:ABMD) CEO Michael R. Minogue sold 5,034 shares of the stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $127.07, for a total value of $639,670.38. Following the completion of the sale, the chief executive officer now directly owns 215,782 shares of the company’s stock, valued at approximately $27,419,418.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Abiomed Inc. (NASDAQ:ABMD) opened at 126.90 on Thursday. The company has a 50-day moving average price of $120.78 and a 200 day moving average price of $106.06. The stock has a market capitalization of $5.43 billion, a price-to-earnings ratio of 135.00 and a beta of 0.89. Abiomed Inc. has a 12 month low of $67.81 and a 12 month high of $127.19.
Abiomed (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.06. The business had revenue of $103 million for the quarter, compared to analyst estimates of $97.23 million. Abiomed had a return on equity of 11.86% and a net margin of 11.75%. The company’s quarterly revenue was up 40.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.20 EPS. Equities analysts predict that Abiomed Inc. will post $1.17 earnings per share for the current year.
Large investors have recently made changes to their positions in the company. Cypress Capital Management LLC WY purchased a new stake in shares of Abiomed during the second quarter valued at approximately $106,000. Bessemer Group Inc. increased its position in shares of Abiomed by 94.3% in the first quarter. Bessemer Group Inc. now owns 1,226 shares of the company’s stock valued at $116,000 after buying an additional 595 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Abiomed by 28.8% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,243 shares of the company’s stock valued at $136,000 after buying an additional 278 shares in the last quarter. Advisor Group Inc. bought a new position in shares of Abiomed during the second quarter valued at about $204,000. Finally, World Asset Management Inc bought a new position in shares of Abiomed during the second quarter valued at about $209,000. 93.65% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently commented on the company. Jefferies Group reaffirmed a “buy” rating and issued a $125.00 price target on shares of Abiomed in a report on Friday, June 10th. Zacks Investment Research cut Abiomed from a “buy” rating to a “hold” rating in a report on Friday, August 12th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $115.59.
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.